Welcome to our dedicated page for The Beauty Health Company news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on The Beauty Health Company stock.
The Beauty Health Company (SKIN), innovator of Hydrafacial systems and advanced aesthetic technologies since 1997, provides this centralized hub for investors and industry professionals. Our news collection offers immediate access to verified corporate developments, combining regulatory filings with market analysis for complete transparency.
This resource serves as your primary source for tracking earnings announcements, product innovations, and strategic partnerships that shape the medical aesthetics sector. Users benefit from chronological organization of press releases alongside third-party analyses, maintaining balanced perspectives on company milestones.
Content spans critical updates including FDA clearances, international expansion efforts, and clinical study results. Each entry is vetted for relevance to investor priorities and industry trends, with particular emphasis on the company's serum-based technology advancements.
Bookmark this page for real-time updates on SKIN's market movements and professional-grade insights into the $18B global aesthetics industry. Cross-reference our archive with SEC filings using provided document identifiers for complete due diligence capabilities.
BeautyHealth (NASDAQ: SKIN), the company behind Hydrafacial, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time following the results release.
Investors and interested parties can access:
- Live webcast of the call on BeautyHealth's investor relations website
- Supporting materials for the presentation
- Recording of the call (available approximately three hours after conclusion)
The company maintains transparency through various communication channels, including SEC filings, press releases, public conference calls, and their investor relations website, ensuring compliance with Regulation FD disclosure obligations.
BeautyHealth (NASDAQ: SKIN) reported Q4 2024 financial results, with net sales of $83.5 million, down 13.8% year-over-year, and full-year 2024 net sales of $334.3 million, declining 16.0% from 2023.
The company's active install base grew to 34,735 units from 31,446 in the prior year, driving growth in consumable sales. However, overall revenue decreased due to fewer unit placements, impacted by challenging macroeconomic conditions. Q4 gross margin improved to 62.7% from 47.2% in Q4 2023.
The company reported a Q4 net loss of $(10.3) million, relatively flat compared to $(9.4) million in Q4 2023. Adjusted EBITDA improved to $9.0 million from $3.4 million in Q4 2023, driven by lower operational spend and higher gross margins. Cash position stood at $370.1 million as of December 31, 2024.
BeautyHealth (NASDAQ: SKIN) has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close. The company, known for its flagship brand Hydrafacial, will host an investor conference call at 4:30 p.m. Eastern Time following the results release.
Interested parties can access the live webcast and supporting materials through BeautyHealth's investor relations website. A recording of the call will be made available approximately three hours after its conclusion.
BeautyHealth (NASDAQ: SKIN) has appointed Stephen J. Fanning to its Board of Directors, effective December 12, 2024. Fanning, a medical aesthetics veteran and former Hydrafacial Chairman (2016-2020), brings extensive industry experience to the role. His previous positions include President and CEO of Spectrum Solutions, leadership at Z-Medica, Solta Medical, and Johnson & Johnson. He currently serves as Chairman for Champion Manufacturing and LKC Technologies.
Fanning will join both the Nominating & Corporate Governance Committee and the Audit Committee, bringing the total board membership to eight directors. BeautyHealth Executive Chairman Brent Saunders highlighted Fanning's expertise in medical aesthetics and proven track record in driving global growth as valuable assets for the company's future growth and profitability initiatives.
BeautyHealth (NASDAQ: SKIN) has released its 2024 Skintuition Report, highlighting key trends in the beauty and skincare industry. The report reveals significant consumer shifts towards skinimalism and clinically proven treatments. Notable metrics include an 8% increase in Hydrafacial Perk Lip Treatments and a 55% surge in neck and décolleté treatments globally compared to the previous year.
The report identifies key trends for 2025, including the medicalization of beauty, rise of skintellectual consumers, skinimalism revival, focus on beautility, and tailored treatments. The company's Hydralock HA Booster, which triples hydration after one treatment, has become their most successful branded booster launch to date.
The Beauty Health Company (NASDAQ: SKIN) announced its Q3 2024 financial results, reporting net sales of $78.8 million, a decrease of 19.1% year-over-year. Gross margin improved to 51.6% from -12.9% in Q3 2023, driven by the absence of previous charges. Adjusted gross margin increased to 69.5%. Net loss narrowed to $18.3 million from $73.8 million in the prior year. Adjusted EBITDA was $8.1 million, down from $9.1 million in Q3 2023. The company sold 1,118 delivery systems, down from 2,140 units, reflecting a challenging macroeconomic environment. BeautyHealth revised its full-year net sales guidance to $322-$332 million and improved adjusted EBITDA guidance to -$2 to $4 million. Strategic moves included centralizing manufacturing in Long Beach and enhancing its commercial leadership.
FAQ
What is the current stock price of The Beauty Health Company (SKIN)?
What is the market cap of The Beauty Health Company (SKIN)?
